Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Safety issues affecting hemophilia products.

¹Houston Health Science Center and the MD Anderson Cancer Center, the University of Texas, Houston, TX 77030, USA.

Transfusion Medicine Reviews

|July 7, 2001

Summary

Clotting factor concentrates (CFCs) have improved in safety and purity. Different types of CFCs offer various benefits and considerations for hemophilia treatment, with ongoing safety concerns.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System.

Haemophilia : the official journal of the World Federation of Hemophilia·2016

Same author

Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2012

Same author

Human plasma-derived concentrates: preventing thrombosis and controlling haemorrhage.

Haemophilia : the official journal of the World Federation of Hemophilia·2010

Same author

The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report.

Haemophilia : the official journal of the World Federation of Hemophilia·2009

Same author

Linking the world with training and research for improving haemophilia care.

Haemophilia : the official journal of the World Federation of Hemophilia·2008

Same author

Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors.

Haemophilia : the official journal of the World Federation of Hemophilia·2008

Area of Science:

Hematology
Biotechnology
Pharmacology

Background:

Clotting factor concentrates (CFCs) have undergone significant advancements in pathogen safety and product purity.
Current CFCs include intermediate purity, very high purity, and recombinant products for factor VIII and factor IX replacement therapy.

Purpose of the Study:

To review the evolution of CFCs regarding safety and purity.
To discuss the different types of CFCs, their theoretical safety profiles, potential host effects like immunogenicity, and their role in hemophilia management.
To address the challenges in cost-efficacy analysis for product selection, considering emerging safety threats.

Main Methods:

Literature review and synthesis of existing data on clotting factor concentrates.
Comparative analysis of different CFC product types (intermediate purity, very high purity, recombinant).
Discussion of theoretical safety, immunogenicity, and therapeutic niches.

Main Results:

CFCs have evolved from intermediate purity to highly purified and recombinant forms.
Each product type (intermediate, very high purity, recombinant) presents distinct safety considerations, immunogenicity profiles, and therapeutic applications.
The selection of CFCs involves balancing efficacy, safety, and cost, especially in light of potential future threats.

Conclusions:

Advancements in CFC technology have enhanced safety and purity.
Understanding the specific characteristics of each CFC type is crucial for optimal hemophilia therapy.
Ongoing vigilance regarding product safety and cost-effectiveness is essential for hemophilia management.

Related Experiment Videos